Home › Funds › DAGCO, INC. › SLS
DAGCO, INC. position in SLS
SELLAS LIFE SCIENCES GROUP I · Health Care
DAGCO, INC. reported holding 1,336,449 shares of SLS (SELLAS LIFE SCIENCES GROUP I) in its Q3 2026 13F filing — a position valued at US$16.5M, representing 2.85% of its reported portfolio and ranking #11 among its reported holdings. DAGCO, INC. has disclosed SLS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How DAGCO, INC.'s SLS position evolved
DAGCO, INC. first disclosed a stake in SLS in Q4 2025 at 577,540 shares (US$2.2M). The position peaked in Q2 2026 at 1,232,433 shares, worth US$18.2M. Across 4 filings, DAGCO, INC. increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,336,449 shares valued at US$16.5M — an increase of 104,016 shares quarter over quarter.. Notable position changes include a 78% increase in Q1 2026 (shares rose 249% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 577.54K | $2.18M | New |
| Q1 2026 | 1.03M | $4.35M | Add |
| Q2 2026 | 1.23M | $18.19M | Add |
| Q3 2026 | 1.34M | $16.45M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SLS and 13F data
SLS (SELLAS LIFE SCIENCES GROUP I) is a Health Care company. 106 other funds we track also report a position in SLS — the largest reported positions include Sio Capital Management, LLC (US$18.2M), Anson Funds Management LP (US$11.8M), Ikarian Capital, LLC (US$5.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SLS
- Sio Capital Management, LLC 1.23M sh · $18.17M · Q2 2026
- Anson Funds Management LP 800.00K sh · $11.81M · Q2 2026
- Ikarian Capital, LLC 354.70K sh · $5.24M · Q2 2026
- Opus Capital Group, LLC 403.63K sh · $4.97M · Q3 2026
- Rosalind Advisors, Inc. 568.70K sh · $2.30M · Q2 2026
- FULCRUM WEALTH ADVISORS, LLC 85.45K sh · $1.05M · Q3 2026
- VISION FINANCIAL MARKETS LLC 57.00K sh · $701.67K · Q3 2026
- Marathon Trading Investment Management LLC 50.10K sh · $616.73K · Q3 2026
- INSTRUMENTAL WEALTH, LLC 44.91K sh · $552.89K · Q3 2026
FAQ
How long has DAGCO, INC. held SLS?
DAGCO, INC. has disclosed SLS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is DAGCO, INC.'s current position in SLS?
As of Q3 2026, DAGCO, INC. holds 1.34M shares of SLS (SELLAS LIFE SCIENCES GROUP I), valued at $16.45M, representing 2.85% of its reported portfolio and ranking #11.
Has DAGCO, INC. been buying or selling SLS?
In the latest 13F filing (Q3 2026), DAGCO, INC. increased its position in SLS. The position peaked in Q2 2026 at 1.23M shares.
Which other funds hold SLS?
Other major institutional holders of SLS include Sio Capital Management, LLC, Anson Funds Management LP, Ikarian Capital, LLC, among 106 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.